TuHURA Biosciences Receives U.S. Patent For Administration Of DOR Antagonists

TuHURA Biosciences, Inc. (NASDAQ: HURA) has been granted U.S. Patent No. 12,734,168 for its novel approach to administering Delta Opioid Receptor (DOR) antagonists in cancer treatment. The patent covers methods to reprogram immunosuppressive environments in patients with cancer associated with DOR-expressing Myeloid Derived Suppressor Cells (MDSCs) and includes various combination therapies aimed at treating and preventing cancer and metastasis.